Cancer Treatment

NewsApr 22, 2026

IceCure Medical ProSense Revenue Surges 30% in Q1 2026 as Cryoablation Technology Gains Traction

IceCure Medical reports 30%+ revenue growth for ProSense cryoablation systems in Q1 2026, highlighting growing adoption of minimally-invasive tumor treatment.

James Chen, PharmD

News by Topic

More News Topics

Press Releases

Analysis by Topic

More Analysis Topics

Whitepapers

Browse

By Region

Directory

By Region

For Suppliers

For Brands

Resources

Popular Topics

More Topics

Browse

About Us

Get in Touch

Quick Actions

Recent Searches

Popular Topics

Suggestions

IceCure Medical ProSense Revenue Surges 30% in Q1 2026 as Cryoablation Technology Gains Traction